In this episode of the podcast Rob is solo as he interviews Dr. Anath Shalev, a diabetes researcher turned founder of startup TIXiMED. Dr. Shalev discusses the discovery of TixnIP, a protein involved in oxidative stress in beta cells, and its potential for treating diabetes. The conversation covers the development of TIX 100, an oral medication targeting TixnIP, its implications for type 1 and type 2 diabetes, and the differences from existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists.
Topics discussed:
Dr. Anas Shalev's background in diabetes research and founding of Tiximed
Discovery of TixnIP and its role in beta cell health
Potential of TIX 100 as a novel oral medication for diabetes treatment
Comparison of TIX 100 with existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists
Research process behind TixnIP inhibition and development of TIX 100
Future of diabetes care, combination therapies, and impact on patients' lives
Information about TIXiMED, clinical trials, and ways to support the research
00:18 Revolutionizing Diabetes Treatment: From Researcher to Founder
03:47 Revolutionizing Diabetes Treatment: Targeting Beta Cells and Glucagon Levels
13:47 Revolutionizing Diabetes Treatment: Targeting Beta Cells in Type 1 and Type 2 Diabetes
17:35 Revolutionizing Diabetes Treatment with Ticks 100: A Breakthrough in Addressing the Root Cause of the Disease
27:35 The Limitations and Advantages of Verapamil in Diabetes Care
29:47 Advancements in Diabetes Technology and Research: A Look into the Future
33:04 Exploring Diabetes Treatment Innovations with Dr. Shalev
